Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Tagraxofusp for R/R myelofibrosis shows promise

Naveen Pemmaraju • 8 Dec 2019
ASH 2019
Myelofibrosis Myeloproliferative Neoplasms Tagraxofusp

Tagraxofusp (SL-401) is an anti-CD123 therapy that is FDA-approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Here Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, outlines the results from a phase 1/2 trial of tagraxofusp for relapsed/refractory intermediate or high risk myelofibrosis (NCT02268253), a setting where this agent is also hoped to excel. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals